Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 5:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 121 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Nonmalignant Diseases Clear all
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Enriched Hematopoetic Stem Cell Infusion
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
3
States / cities
Louisville, Kentucky • Durham, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced May 21, 2026, 5:56 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboplatin, docetaxel, ifosfamide, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
Cancer Treatment Centers of America
Other
Eligibility
Up to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Zion, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced May 21, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Immunodeficiency Syndrome, Non-Cancer Diagnosis
Interventions
Alemtuzumab, Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Total-Body Irradiation
Biological · Procedure · Drug + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 54 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
6
States / cities
Oakland, California • Cleveland, Ohio • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced May 21, 2026, 5:56 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions
Interventions
data collection
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced May 21, 2026, 5:56 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Leukemia, Lymphoma, Neuroblastoma, Immunodeficiencies, Anemia
Interventions
Alemtuzumab, Total Body Irradiation, Melphalan, Busulfan, Phenytoin, Fludarabine, Cyclophosphamide, Horse Antithymocyte Globulin, Rabbit Antithymocyte Globulin, Thiotepa
Drug · Radiation
Lead sponsor
Columbia University
Other
Eligibility
Up to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced May 21, 2026, 5:56 PM EDT
Available No phase listed Expanded access
View directory record Official record
Conditions
Hematologic Malignancies, Inborn Errors of Metabolism Disorders, Immune Deficiencies
Interventions
CliniMACS CD34 Reagent System
Biological
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
Up to 65 Years
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced May 21, 2026, 5:56 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Hematologic Diseases
Interventions
Allogeneic Stem Cell Transplant, CliniMACS TCR α/β Reagent Kit and CliniMACS CD19
Biological · Device
Lead sponsor
Alice Bertaina
Other
Eligibility
1 Month to 60 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced May 21, 2026, 5:56 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Malignant Diseases, Non-malignant Diseases
Interventions
CliniMACS CD34+ cell enrichment and T-cell depletion
Device
Lead sponsor
Rajni Agarwal
Other
Eligibility
Up to 35 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2023 · Synced May 21, 2026, 5:56 PM EDT
Available No phase listed Expanded access
View directory record Official record
Conditions
Benign Neoplasm, Bone Marrow Transplantation Recipient, Hematopoietic Cell Transplantation Recipient, Malignant Neoplasm
Interventions
Bone Marrow Transplantation, CliniMACS CD34 Reagent System, Peripheral Blood Stem Cell Transplantation
Procedure · Device
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 70 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced May 21, 2026, 5:56 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
Multispectral Digital Colposcope (MDC)
Device
Lead sponsor
British Columbia Cancer Agency
Other
Eligibility
18 Years and older · Female only
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Brooklyn, New York • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced May 21, 2026, 5:56 PM EDT
Active, not recruiting Not applicable Interventional Results available
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Hemophagocytic Lymphohistiocytoses, Primary Immunodeficiency Diseases, Hemoglobinopathies, Severe Aplastic Anemia, Cytopenia, Bone Marrow Failure Syndrome, Severe Chronic Active Epstein-Barr Virus Infection
Interventions
CliniMACS
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced May 21, 2026, 5:56 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Cervical Cancer, Precancerous/Nonmalignant Condition
Interventions
tretinoin
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
14 Years and older · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced May 21, 2026, 5:56 PM EDT
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Neurofibromatosis Type 1, Neurofibromatosis 1, Neurofibromatosis (Nonmalignant), Cutaneous Neurofibroma
Interventions
Evaluation of the natural history of cutaneous neurofibromas
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
1 Year to 100 Years
Enrollment
500 participants
Timeline
2021 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced May 21, 2026, 5:56 PM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Inherited Metabolic Disorders (IMD)
Interventions
Safety and efficacy assessments
Other
Lead sponsor
Magenta Therapeutics, Inc.
Industry
Eligibility
Up to 16 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2021 · Synced May 21, 2026, 5:56 PM EDT
Terminated Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders, Chediak-Higashi Syndrome, Griscelli Syndrome, Immunologic Diseases, Langerhans-Cell Histiocytosis, Hematologic Diseases
Interventions
Stem Cell Transplant, Myeloablative conditioning regimen
Procedure · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced May 21, 2026, 5:56 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Dysphagia
Interventions
Dilation, Triamcinolone Injection, Esophagogastroduodenoscopy (EGD)
Procedure · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced May 21, 2026, 5:56 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies, Non-malignant Disorders
Interventions
Treatment Plan 1: Stratum 1, Treatment Plan 2: Strata 2, 3, or 4, GVHD Regimen A: UCB Recipients, GVHD Regimen B: BM Recipients
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 20 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2031
U.S. locations
25
States / cities
Phoenix, Arizona • Orange, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced May 21, 2026, 5:56 PM EDT
Not listed No phase listed Observational
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Colo-rectal Cancer
Interventions
no intervention will be given to patients.
Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 99 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced May 21, 2026, 5:56 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Leukemia, Lymphoma, Bone Marrow Failure, Immunodeficiencies, Histiocytosis, Sickle Cell Disease, Beta Thalassemia, Inborn Errors of Metabolism
Interventions
Full Intensity with TBI, Full Intensity, Reduced Intensity, Reduced Intensity (Fanconi)
Drug
Lead sponsor
New York Medical College
Other
Eligibility
Up to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced May 21, 2026, 5:56 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Chronic Venous Disorder, Venous Outflow Obstruction, Symptomatic Venous Outflow Obstruction of Iliofemoral Vein
Interventions
Veniti Vici™ Venous Stent System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
16
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced May 21, 2026, 5:56 PM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis, Inherited Bone Marrow Failure Syndrome, Hemoglobinopathies, Metabolic Disorders
Interventions
BPX-501 and Rimiducid
Biological
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
4 Months to 55 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 24, 2024 · Synced May 21, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Naldemedine, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
99
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced May 21, 2026, 5:56 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
aldesleukin, recombinant interferon alfa
Biological
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 1999
U.S. locations
5
States / cities
Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated May 11, 2011 · Synced May 21, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Naldemedine, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
49
States / cities
Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced May 21, 2026, 5:56 PM EDT